For immediate release
February 26, 2015

Contact
Alise Fisher
571-483-1354
alise.fisher@asco.org

Orlando – Six studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2015 Genitourinary Cancers Symposium, taking place February 26-28 in Orlando. These notable abstracts investigate several approaches to prostate cancer – short-term ADT, brachytherapy, cabozantinib, docetaxel, and statins – as well as the association between obesity and fatal kidney cancer.

Experts in genitourinary cancers are available on-site to comment on the studies below.

Abstract 3:
ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.

Oral Abstract Session: Prostate Cancer
Thursday, February 26, 2015: 1:30 – 1:40 PM
Rosen, Gatlin Ballroom C

W. James Morris, MD, FRCPC
BC Cancer Agency
Vancouver, Canada

Abstract 5:
Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial.

Oral Abstract Session: Prostate Cancer
Thursday, February 26, 2015: 1:50 – 2:00 PM
Rosen, Gatlin Ballroom C

Abdenour Nabid, MD, FRCP(C)
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Canada
Abstract 139:
*Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).*

Oral Abstract Session: Prostate Cancer
Thursday, February 26, 2015: 1:00 – 1:10 PM
Rosen, Gatlin Ballroom C
Matthew Raymond Smith, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts

Abstract 140:
*Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.*

Oral Abstract Session: Prostate Cancer
Thursday, February 26, 2015: 1:10 – 1:20 PM
Rosen, Gatlin Ballroom C
Gwenaelle Gravis, MD
Institut Paoli Calmettes
Marseille, France

Abstract 148:
*Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.*

General Poster Session A: Prostate Cancer
Thursday, February 26, 2015: 11:30 AM – 1:00 PM
Thursday, February 26, 2015: 5:15 – 6:45 PM
Rosen, Gatlin Ballroom B
Lauren Christine Harshman, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Abstract 414:
*The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.*

General Poster Session C: Renal Cancer
Saturday, February 28, 2015: 7:00 – 7:55 AM
Saturday, February 28, 2015: 11:30 AM – 1:00 PM
Rosen, Gatlin Ballroom B
Kathryn Wilson, ScD
Harvard T.H. Chan School of Public Health
Boston, Massachusetts

2015 Genitourinary Cancers Symposium News Planning Team
Charles J. Ryan, MD, American Society of Clinical Oncology (ASCO); Howard M. Sandler, MD, MS, American Society for Radiation Oncology (ASTRO); and Fred M. Saad, MD, FRCS, Society of Urologic Oncology (SUO).
View the disclosures for the News Planning Team.

ATTRIBUTION TO THE 2015 GENITOURINARY CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.